Quadria Capital, a healthcare-focused private equity firm managing over $4.2 billion in assets, is among 4-5 investors evaluating a potential acquisition of an 80-85% stake in Samarth Lifesciences, a Mumbai-based manufacturer of critical care drugs. This deal could value the company at around ₹4,500 crore. The promoters of Samarth are expected to retain a 15-20% stake post-transaction. Samarth aims to raise fresh capital to support its growth initiatives, including investments in new factories and expanding its domestic presence. The company has seen significant growth, reporting sales of ₹727 crore with a 16% compounded annual growth rate, outpacing the industry average of 10-12%. However, previous negotiations with global investors like EQT and Warburg Pincus fell through due to valuation disagreements, as the promoters seek a valuation multiple of nearly 30 times their earnings before interest, tax, depreciation, and amortization (EBITDA) of ₹160-170 crore in FY26. Samarth has established a strong reputation in the injectables and sterile segment, with successful products like Caprin, Poly B, and Mucomix, and has expanded into international markets including the UK, South America, Southeast Asia, and Africa.